» Articles » PMID: 25941611

Tumor Stroma-derived Factors Skew Monocyte to Dendritic Cell Differentiation Toward a Suppressive CD14 PD-L1 Phenotype in Prostate Cancer

Overview
Journal Oncoimmunology
Date 2015 May 6
PMID 25941611
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor-associated stromal myofibroblasts are essential for the progression and metastatic spread of solid tumors. Corresponding myeloid cell infiltration into primary tumors is a negative prognostic factor in some malignancies. The aim of this study was to define the exact role of stromal myofibroblasts and stromal factors in early prostate carcinoma (PCa) regulating monocyte infiltration and differentiation into dendritic cells (DCs). Epithelial and stromal primary cultures were generated from PCa biopsies and their purity confirmed. Stromal cells produced significantly more of the (C-C) motif chemokine ligand 2 (CCL2), interleukin 6 (IL-6) and transforming growth factor β (TGFβ) than epithelial cells. Monocyte chemoattraction was predominantly due to stromal-derived factors, mainly CCL2. DCs generated in the presence of stromal (but not epithelial) factors upregulated CD209, but failed to downregulate the monocyte marker CD14 in a signal transducer and activator of transcription 3 (STAT3)-dependent manner. Monocytes exposed to stromal factors did not produce detectable amounts of IL-10, however, upon lipopolysaccharide stimulation, stromal factor generated dendritic cells (sDC) produced significantly more IL-10 and less IL-12 than their conventional DC counterparts. sDC failed to cross-present tumor-antigen to CD8 T cells and suppressed T-cell proliferation. Most importantly, sDC expressed significantly elevated levels of programmed cell death ligand-1 (PD-L1) in a primarily STAT3 and IL-6-dependent manner. In parallel with our findings , tumor-infiltrating CD14 cells were found to express both PD-L1 and CD209, and a higher percentage of tumor-associated CD3 T cells expressed programmed cell death-1 (PD-1) molecules compared to T cells in blood. These results demonstrate a hitherto undescribed, fundamental contribution of tumor-associated stromal myofibroblasts to the development of an immunosuppressive microenvironment in early PCa.

Citing Articles

Monocyte and Macrophage Functions in Oncogenic Viral Infections.

Echevarria-Lima J, Moles R Viruses. 2024; 16(10).

PMID: 39459945 PMC: 11512331. DOI: 10.3390/v16101612.


The immunoreactive signature of monocyte-derived dendritic cells from patients with Down syndrome.

Nakashima K, Imai T, Shiraishi A, Unose R, Goto H, Nagatomo Y Clin Exp Immunol. 2024; 217(3):291-299.

PMID: 38916251 PMC: 11310712. DOI: 10.1093/cei/uxae048.


Inflammation and tumor microenvironment.

Niu T, Zhou F Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024; 48(12):1899-1913.

PMID: 38448384 PMC: 10930746. DOI: 10.11817/j.issn.1672-7347.2023.230231.


Dendritic cells as orchestrators of anticancer immunity and immunotherapy.

Heras-Murillo I, Adan-Barrientos I, Galan M, Wculek S, Sancho D Nat Rev Clin Oncol. 2024; 21(4):257-277.

PMID: 38326563 DOI: 10.1038/s41571-024-00859-1.


A tumor-associated heparan sulfate-related glycosaminoglycan promotes the generation of functional regulatory T cells.

Martin-Cruz L, Vinuela M, Kalograiaki I, Angelina A, Oquist-Phillips P, Real-Arevalo I Cell Mol Immunol. 2023; 20(12):1499-1512.

PMID: 37990034 PMC: 10687014. DOI: 10.1038/s41423-023-01096-9.


References
1.
Miller A, Pisa P . Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother. 2005; 56(1):81-7. PMC: 11041923. DOI: 10.1007/s00262-005-0110-x. View

2.
Southall P, Boxer G, Bagshawe K, Hole N, Bromley M, Stern P . Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer. 1990; 61(1):89-95. PMC: 1971328. DOI: 10.1038/bjc.1990.20. View

3.
Herrera M, Herrera A, Dominguez G, Silva J, Garcia V, Garcia J . Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Sci. 2013; 104(4):437-44. PMC: 7657228. DOI: 10.1111/cas.12096. View

4.
Loberg R, Day L, Harwood J, Ying C, St John L, Giles R . CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia. 2006; 8(7):578-86. PMC: 1601934. DOI: 10.1593/neo.06280. View

5.
Peehl D . Primary cell cultures as models of prostate cancer development. Endocr Relat Cancer. 2005; 12(1):19-47. DOI: 10.1677/erc.1.00795. View